# Phase I Study of Oral DFP-11207 in Solid Tumors

> **NCT02171221** · PHASE1 · COMPLETED · sponsor: **Delta-Fly Pharma, Inc.** · enrollment: 23 (actual)

## Conditions studied

- Solid Tumors
- Cancer

## Interventions

- **DRUG:** Oral DFP-11207

## Key facts

- **NCT ID:** NCT02171221
- **Lead sponsor:** Delta-Fly Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06
- **Primary completion:** 2018-09-13
- **Final completion:** 2018-09-13
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2019-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02171221

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02171221, "Phase I Study of Oral DFP-11207 in Solid Tumors". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02171221. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*